CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients

Frontiers in Aging

Fatih M. Uckun²  Justin Watts³ 

[1] Aptevo Therapeutics, Seattle, WA, United States;Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN, United States;University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, United States;

关键词: CD123;    bispecific antibody;    MDSC;    MDS;    T-cells;    APVO436;   

DOI  :  10.3389/fragi.2021.757276

来源: DOAJ

【 摘 要 】

There is an urgent need to identify effective strategies to prevent leukemic transformation and induce sustained deep remissions in adult high-risk myelodysplastic syndrome (MDS) patients. This article discusses the clinical impact potential of bispecific antibodies (BiAB) capable of redirecting host T-cell cytotoxicity in an MHC-independent manner to malignant clones as well as immunosuppressive myeloid-derived suppressor cells (MDSC) as a new class of anti-MDS drug candidates. T-cell engaging BiAB targeting the CD123 antigen may help delay disease progression in high-risk adult MDS and potentially reduce the risk of transformation to secondary AML.

【 授权许可】

Unknown